Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Insilico Medicine secures $123 million in Series E financing led by Value Partners. The funding focuses on advancing AI technologies in life sciences.

PRIVATEAug 20, 2026•about 4 hours ago

Amount Raised

¥123 Million

Round Type

Series E

CambridgeBiotechnology

Investors

Pudong Development GroupPudong Venture CapitalValue Partners

Description

Insilico Medicine has closed a $123 million Series E financing round with Value Partners as the lead investor. This funding aims to integrate AI technologies within the life sciences sector. Value Partners, along with Pudong Venture Capital and Pudong Development Group, has laid the groundwork for this investment. The collaboration seeks to unlock significant opportunities in scientific discovery through AI advancements.

Company Information

Company

Insilico Medicine

Location

1000 Massachusetts Avenue, Suite 126

Cambridge, Massachusetts, United States

About

Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-stage automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine.

Don't miss Insilico Medicine's next move

Get an email the moment Insilico Medicine raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Suggested for you
2 contacts
Verified contactsFeng R., co-CEO, CSO, Head of Drug R&D hidden
Predictive Intelligence
Strategic

ML-powered predictions for Insilico Medicine's next move

Learn about Strategic plan

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Insilico Medicine raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.